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ing DIF were related to the dimension “precise movement” and were detected in 
the Spain-Italy comparison (Δ R2 [left hand] = 0.2165, Δ R2 [right hand] = 0.1618) 
and in the Spain-France comparison (Δ R2 [left hand] = 0.1571, Δ R2 [right hand] 
= 0.1578). ConClusions: Globally, these data support the H-CSRI cross-cultural 
validity. Further analyses should be conducted to confirm if those particular items 
need to be revised in the Spanish version.
PRM137
SeveRity And FunctionAl diSAbility oF PAtientS With occuPAtionAl 
contAct deRMAtitiS: vAlidAtion oF the GeRMAn veRSion oF the 
occuPAtionAl contAct deRMAtitiS diSeASe SeveRity index (oddi)
Apfelbacher C.1, Popielnicki A.2, Bauer A.3, Diepgen T.L.4, Elsner P.5, Dawsey R.6, Mahler V.7, 
Molin S.8, Schmitt J.9, Weisshaar E.10, Ofenloch R.F.10
1UR - University of Regensburg, Regensburg, Germany, 2TransPerfect, Boston, MA, USA, 
3University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany, 
4University Heidelberg, Heidelberg, Germany, 5University Hospital Jena, Jena, Germany, 
6TransPerfect, Atlanta, GA, USA, 7University Hospital of Erlangen, Friedrich-Alexander-University 
Erlangen-Nuremberg, Erlangen, Germany, 8Ludwig-Maximilians-University Munich, München, 
Germany, 9Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany, 
10University Hospital Heidelberg, Heidelberg, Germany
objeCtives: The Occupational Contact Dermatitis Disease Severity Index (ODDI) 
was designed in Australia to measure severity and functional disability in patients 
with occupational contact dermatitis (OCD) of the hands. The psychometric prop-
erties of the German version of the ODDI are unclear. Our objective was to investi-
gate the validity and reliability of the German ODDI version. Methods: The ODDI 
was translated and linguistically validated into German for Germany, following 
industry standard procedures of concept definition, dual forward translation, back 
translation and reconciliation, and clinician review. Once the German version was 
available, data was drawn from the baseline assessment (T0) and first follow-up 
(T1) of the German chronic hand eczema (CHE) registry (carpe). Spearman cor-
relations of the ODDI with reference measures were computed to assess valid-
ity. Cronbach’s alpha was calculated as a measure of internal consistency and the 
intraclass correlation coefficient (ICC) to assess retest-reliability. Smallest real dif-
ference (SRD) and minimal clinical important difference (MCID) were calculated 
to assess sensitivity to change. Physician Global Assessment (PGA) was used as an 
anchor for the MCID. Results: 422 patients (54.5% female, mean age: 45.1 years) 
were included for analysis. Cronbach’s α was found to be 0.73. The ICC was 0.79. 
Correlations of the ODDI total and the Dermatology Life Quality Index (rho= 0.36) 
as well as the PGA (rho= 0.48) and patient-assessed disease severity (rho= 0.40) 
were of moderate strength. The MCID (1.29) was found to be smaller than the SRD 
(1.87). ConClusions: The German ODDI version is reliable and valid to measure 
functional impairment and disease severity in patients suffering from OCD. The 
MCID falls within the range of measurement error and should not be used.
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objeCtives: To evaluate the predictive performance of a previously published 
mapping algorithm for converting the prostate cancer specific instrument FACT-P 
(Functional Assessment of Cancer Therapy–Prostate) to EQ-5D utility values (UK tariff) 
on a sample with a different disease stage than the one on which the model was 
generated [Skaltsa et. al. ViH 2014]. Methods: We applied a previously developed 
algorithm to the data obtained from a randomized, double-blind, placebo-controlled 
phase 3 trial in asymptomatic/mildly symptomatic chemo-naïve mCRPC patients. 
The trial collected EQ-5D and FACT-P data at baseline and until treatment discon-
tinuation. The mapping model was developed on mCRPC patients in a post-chemo 
setting, included the FACT-P subscale scores and baseline variables and used sepa-
rate algorithms for patients with good and poor health defined as a FACT-P score 
exceeding or not 76. Model performance was assessed by mean absolute error (MAE) 
and root mean squared error (RMSE). Results: The testing dataset contained 1,669 
patients with baseline and ≥ 1 post-baseline scores. The average baseline EQ-5D 
utility and FACT-P total score were 0.844 and 119.5 respectively. Percentage of per-
fect health was 37% across all visits (ceiling effect). The average (across all visits) 
observed and predicted EQ-5D utility index value was 0.823 and 0.842, respectively. 
The model yields accurate predictions (MAE= 0.107; RMSE= 0.150) comparable to 
the ones obtained on the development sample (MAE= 0.117; RMSE= 0.162). The 
model predicts well for milder health states, but overpredicts for the more severe 
ones (EQ-5D utility≤ 0.5: MAE= 0.436, RMSE= 0.258; EQ-5D utility > 0.5: MAE= 0.096, 
RMSE= 0.125). ConClusions: Although external validation is recommended using 
similar samples, our findings show that the algorithm developed in the post-chemo 
setting performed well in a pre-chemo setting in mCRPC patients, although over-
predicts for severe states. This model seems suitable for predicting utility values for 
economic evaluation when a preference-based measure is absent in chemo-naïve 
mCRPC populations.
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objeCtives: In economic evaluations in oncology, survival data is typically extrap-
olated without taking into account prognostic factors. If individual level trial data 
are available, patient and disease characteristics observed at baseline are consid-
ered. However, survival models typically disregard information that are not known 
at baseline, e.g. response to treatment, but that may be valuable for the prognosis 
of patients and hence for decision making. In this study we present a parametric 
survival model that included response to treatment over time. Methods: Data 
from 99 patients with late-stage soft tissue sarcoma from a clinical trial was used. 
Survival information and the percentage change in the sum of the longest diam-
eters of target lesions (i.e. the basis for response evaluation) measured repeatedly 
during follow-up were utilized. A joint model was estimated linking a random 
effects sub-model for the change of tumor size with a Weibull sub-model for the 
survival outcome. The association between change of tumor size over time and 
overall survival was assessed. Several different functional forms were explored 
to model the tumor size data and the best fitting model was selected. Results: 
The median follow-up time in the trial was 1.6 years; 63 patients died. On aver-
age, 4.8 measurements on tumor size were available per patient. A flexible cubic 
B-spline sub-model provided the repeatedly measured tumor size change data the 
best model fit. The association between tumor growth and overall survival was 
marginally statistically significant with a P value of less than 0.10. ConClusions: 
The presented joint model demonstrated that response to treatment over time 
may be important to consider when building survival models for health economic 
evaluations in oncology. The model explicitly incorporated the heterogeneity of 
patients not observed at baseline providing a clinically relevant survival model. 
Individual survival predictions can be prepared using patient-specific history of 
tumor growth.
ReSeARch on MethodS – Patient-Reported outcomes Studies
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objeCtives: The Huntington Quality of Life Instrument (H-QoL-I) is the first self-
reported specific instrument developed to assess the health-related QoL (HRQoL) 
of patients with Huntington’s disease (HD). It includes three subscales: motor 
(4 Likert-type items), psychology (4 Likert-type items) and socializing (3 Likert-
type items). The aim of the study was to assess whether patients from different 
countries respond differently to the H-QoL-I instrument. Methods: Data were 
from the European study of HD burden (EURO-HDB) survey and included data 
across 6 countries: France, Germany, Italy, Spain, Poland and the USA. The Differential 
Item Functioning (DIF) method was adopted to examine whether patients from dif-
ferent countries with the same characteristics had different probability of giving 
a certain response on H-QoL-I. An item was considered as displaying a DIF if the 
p-value associated with the two-degree-of-freedom Chi-squared test comparing the 
two ordinal logistic regressions (with/without country effect and an interaction term 
between the total rest score and country) was lower than 0.01 and the Zumbo-Thomas 
effect size was higher than 0.130. Zumbo-Thomas effect size measure and associated 
p-value were calculated for each item and for all pairs of countries (i.e. 15 combina-
tions). Results: The study included 633 patients (176 French, 124 Italian, 44 German, 
60 Polish, 59 Spanish and 170 American). No DIF was detected across all combinations 
of countries for all items. Sixteen pairwise Zumbo-Thomas effect size measures refer-
ring to 7 items were found significant but were lower than 0.130. ConClusions: This 
study did not detect any variation across the studied countries in the assessment of 
HRQoL of HD patients using the H-QoL-I instrument. These results support the cross-
cultural validity of the H-QoL-I.
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objeCtives: The H-CSRI is the first clinimetric self-reported instrument for patients 
with Huntington’s disease (HD). It includes three subscales: motor (13 Likert-type 
items in 4 dimensions), functional (7 Yes/No questions) and behavioural (13 Likert-
type items in 4 dimensions). The aim of the study was to assess whether patients 
from different countries respond differently to H-CSRI. Methods: Data were from 
the European study of HD burden (EURO-HDB) survey and included data across 6 
countries: France, Germany, Italy, Spain, Poland and the USA. The Differential Item 
Functioning (DIF) method was adopted to examine whether patients from different 
countries with the same characteristics had different probability of giving a certain 
response on H-CSRI. An item was considered as displaying a DIF if the p-value 
associated with the two-degree-of-freedom Chi-squared test comparing the two 
ordinal logistic regressions (with/without country effect and an interaction term 
between the total rest score and country) was lower than 0.01 and the Zumbo-
Thomas effect size was higher than 0.130. Zumbo-Thomas effect size measure and 
associated p-value were calculated for each item and for all pairs of countries (i.e. 
15 combinations). Results: The study included 633 patients (176 French, 124 
Italian, 44 German, 60 Polish, 59 Spanish and 170 American). Almost all the 
items (24 of 26) didn’t show any cross/cultural difference. The two items show-
